Skip to main
VNRX

Volitionrx Limited (VNRX) Stock Forecast & Price Target

Volitionrx Limited (VNRX) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

VolitionRX Ltd is positioned for significant growth in the diagnostics market, particularly through the introduction of a feline assay that could potentially double its total addressable market for companion animal testing, capitalizing on increasing awareness of feline oncology. The company's expanded scientific narrative supports a combined annualized total addressable market of approximately $36 billion for multi-cancer early detection and minimal residual disease, bolstering its strategic partnerships and commercialization efforts. Furthermore, the development and market entry of the Nu.Q Vet Feline Test and the establishment of additional laboratory partnerships enhance Volition's geographic reach and establish new recurring revenue streams, reinforcing a positive long-term outlook for the company.

Bears say

VolitionRX Ltd has faced challenges in achieving significant revenue growth, with recent financial reports indicating inconsistent performance and lack of widespread market adoption of its blood tests. The company's dependence on the development of its Nucleosomics platform has resulted in substantial research and development expenses, contributing to ongoing operating losses and raising concerns about long-term sustainability. Additionally, competitive pressures within the diagnostics space, coupled with potential regulatory hurdles, have further exacerbated uncertainty regarding VolitionRX's future financial performance.

Volitionrx Limited (VNRX) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Volitionrx Limited and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Volitionrx Limited (VNRX) Forecast

Analysts have given Volitionrx Limited (VNRX) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Volitionrx Limited (VNRX) has a Strong Buy consensus rating as of Mar 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Volitionrx Limited (VNRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.